Carl L. Gordon Purchases 47,502 Shares of MBX Biosciences, Inc. (NYSE:MBX) Stock

MBX Biosciences, Inc. (NYSE:MBX) Director Carl L. Gordon bought 47,502 shares of the firm’s stock in a transaction that occurred on Friday, February 14th. The stock was bought at an average price of $9.87 per share, with a total value of $468,844.74. Following the completion of the acquisition, the director now owns 3,205,930 shares of the company’s stock, valued at $31,642,529.10. This trade represents a 1.50 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

MBX Biosciences Stock Up 5.4 %

NYSE:MBX opened at $11.83 on Friday. The company has a fifty day moving average of $14.05. MBX Biosciences, Inc. has a 12-month low of $8.63 and a 12-month high of $27.50.

Institutional Trading of MBX Biosciences

A number of institutional investors have recently bought and sold shares of MBX. BNP Paribas Financial Markets purchased a new stake in MBX Biosciences during the 4th quarter worth about $27,000. Virtus ETF Advisers LLC purchased a new stake in MBX Biosciences during the 4th quarter worth about $64,000. Deutsche Bank AG purchased a new stake in MBX Biosciences during the 4th quarter worth about $80,000. Corebridge Financial Inc. purchased a new stake in MBX Biosciences during the 4th quarter worth about $103,000. Finally, Wells Fargo & Company MN acquired a new stake in shares of MBX Biosciences during the fourth quarter worth about $108,000.

MBX Biosciences Company Profile

MBX Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism.